Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     

VIVEVE MEDICAL, INC.

(VIVE)
  Report
Delayed Nasdaq  -  01:29 2022-10-05 pm EDT
0.6992 USD   +5.06%
10/04Viveve Medical, Inc. : Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K)
AQ
09/27Viveve Medical, Inc. : Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K)
AQ
09/27Viveve Medical, Inc. Launches Rebranding Initiative to Reflect Focus on Treatment of Female Stress Urinary Incontinence in Anticipation of U.S. Pivotal Pursuit Trial Readout
CI
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
09/29/2022 09/30/2022 10/03/2022 10/04/2022 10/05/2022 Date
0.7001(c) 0.68(c) 0.689(c) 0.6655(c) 0.6992 Last
3 919 7 249 10 245 35 415 8 132 Volume
-1.39% -2.87% +1.32% -3.41% +5.06% Change
More quotes
Estimated financial data (e) (USD)
Sales 2022 7,02 M - -
Net income 2022 -28,5 M - -
Net Debt 2022 - - -
P/E ratio 2022 -0,25x
Yield 2022 -
Sales 2023 11,2 M - -
Net income 2023 -27,2 M - -
Net Debt 2023 - - -
P/E ratio 2023 -0,32x
Yield 2023 -
Capitalization 7,10 M 7,10 M -
Capi. / Sales 2022 1,01x
Capi. / Sales 2023 0,63x
Nbr of Employees 47
Free-Float 100,0%
More Financials
Company
Viveve Medical, Inc. designs, develops, manufactures, and markets a platform medical technology, Cryogen-cooled Monopolar Radiofrequency (CMRF). The Company's CMRF technology is delivered through a radiofrequency (RF) generator, handpiece and treatment tip, that collectively, is referred to as the Viveve System. The Viveve System is marketed for the non-invasive treatment of vaginal introital laxity, sexual... 
More about the company
Ratings of Viveve Medical, Inc.
Trading Rating :  -
Investor Rating : 
ESG Refinitiv : 
-
More Ratings
All news about VIVEVE MEDICAL, INC.
10/04Viveve Medical, Inc. : Regulation FD Disclosure, Financial Statements and Exhibits (form 8..
AQ
09/27Viveve Medical, Inc. : Regulation FD Disclosure, Financial Statements and Exhibits (form 8..
AQ
09/27Viveve Medical, Inc. Launches Rebranding Initiative to Reflect Focus on Treatment of Fe..
CI
09/23Viveve Medical : Registration statement for specified transactions by certain issuers
PU
09/22Viveve Medical : Current report filing
PU
09/22Viveve Medical, Inc. : Regulation FD Disclosure, Financial Statements and Exhibits (form 8..
AQ
09/15Viveve Medical : Current report filing
PU
09/15Viveve Medical, Inc. : Regulation FD Disclosure, Financial Statements and Exhibits (form 8..
AQ
09/01Viveve Medical : Current report filing
PU
09/01Viveve Medical, Inc. : Regulation FD Disclosure, Financial Statements and Exhibits (form 8..
AQ
08/11Transcript : Viveve Medical, Inc., Q2 2022 Earnings Call, Aug 11, 2022
CI
08/11Viveve Medical : Reports Second Quarter 2022 Financial Results and Provides Corporate Upda..
PU
08/11Viveve Medical : Current report filing
PU
08/11Viveve Medical : Quarterly report pursuant to Section 13 or 15(d)
PU
08/11VIVEVE MEDICAL, INC. Management's Discussion and Analysis of Financial Condition and R..
AQ
More news
News in other languages on VIVEVE MEDICAL, INC.
09/27Viveve Medical, Inc. Lance une initiative de rebranding pour refléter l'accent mis sur ..
08/11Viveve Medical, Inc. annonce ses résultats pour le deuxième trimestre et le semestre cl..
08/11Earnings Flash (VIVE) VIVE MEDICAL affiche un chiffre d'affaires de 1,8 million de doll..
07/12Viveve Medical déclare que l'Office de la propriété intellectuelle de Taiwan a accordé ..
05/12Earnings Flash (VIVE) VIVE MEDICAL annonce un chiffre d'affaires de 1,6 million de doll..
More news
Analyst Recommendations on VIVEVE MEDICAL, INC.
More recommendations
Chart VIVEVE MEDICAL, INC.
Duration : Period :
Viveve Medical, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends VIVEVE MEDICAL, INC.
Short TermMid-TermLong Term
TrendsBearishNeutralBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 2
Last Close Price 0,67 $
Average target price 4,68 $
Spread / Average Target 602%
EPS Revisions
Managers and Directors
Scott C. Durbin Chief Executive Officer & Director
Jim B. Robbins CFO, Chief Accounting Officer & Senior VP-Finance
Steven L. Basta Chairman
Marty Kerber Vice President-Research, Development & Operations
Doug Massey Vice President-Clinical & Medical Affairs
Sector and Competitors
1st jan.Capi. (M$)
VIVEVE MEDICAL, INC.-41.62%7
THERMO FISHER SCIENTIFIC-19.08%211 539
DANAHER CORPORATION-15.18%202 994
INTUITIVE SURGICAL, INC.-43.91%71 972
BOSTON SCIENTIFIC CORPORATION-6.12%58 739
EDWARDS LIFESCIENCES CORPORATION-32.71%54 047